{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-018436","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.985717+00:00","generated_at":"2026-06-05T19:34:05.409539+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Intellia reports Q4 net loss $132.2M; cash $1.0B; on track for Phase 3 NTLA-2001 in Q1 2024","bullets":["Q4 2023 net loss $132.2M vs $113.4M YoY; R&D expenses rose $9.0M to $109.0M.","Cash, equivalents and securities $1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.","On track to dose first patient in Phase 3 MAGNITUDE trial (NTLA-2001) for ATTR cardiomyopathy in Q1 2024.","Plan to initiate Phase 3 of NTLA-2002 for hereditary angioedema in 2H24; positive interim Phase 1 data published in NEJM.","Expanding pipeline: Phase 1 for NTLA-3001 (AATD) expected in 2024; collaboration with ReCode for cystic fibrosis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-018436","json":"https://secwatch.observer/filing/0000950170-24-018436.json","markdown":"https://secwatch.observer/filing/0000950170-24-018436.md","text":"https://secwatch.observer/filing/0000950170-24-018436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/0000950170-24-018436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/ntla-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:34:05.409539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b2a48e2c25edd60eac7b59b84775be70b63b3413","claim":"Intellia Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/0000950170-24-018436-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}